Human mesenchymal stromal cells: Identifying assays to predict potency for therapeutic selection

Stem Cells Translational Medicine

Volumn 2, Issue 2, 2013, Pages 151-158

  Deskins, Desirae L ^a,b   Bastakoty, Dikshya ^a   Saraswati, Sarika ^a   Shinar, Andrew ^a   Holt, Ginger E ^a   Younga, Pampee P ^a,b  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Clinical trials; Mesenchymal stem cells; Stem cell transplantation; Stem cells; Tissue regeneration

Indexed keywords

5' NUCLEOTIDASE; CD14 ANTIGEN; CD20 ANTIGEN; CD34 ANTIGEN; CD45 ANTIGEN; ENDOGLIN; THY 1 ANTIGEN;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW; CELL COUNT; CELL GROWTH; CELL LINEAGE; CELL MEMBRANE POTENTIAL; CELL PROLIFERATION; CELL THERAPY; CELL VIABILITY; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; GRANULATION TISSUE; GROWTH RATE; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE TEST; IMMUNOHISTOCHEMISTRY; MALE; MESENCHYMAL STROMA CELL; MOUSE; NONHUMAN; NORMAL HUMAN; PHENOTYPE; VASCULARIZATION;

EID: 84876509097     PISSN: 21576564     EISSN: 21576580     Source Type: Journal    
DOI: 10.5966/sctm.2012-0099     Document Type: Article

References (36)

1. Pittenger MF, Mackay AM, Beck SC et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999;284:143-147.
2. Caplan AI. Mesenchymal stem cells. J Orthop Res 1991;9:641-650.
3. Muraglia A, Cancedda R, Quarto R. Clonal mesenchymal progenitors from human bone marrow differentiate in vitro according to a hierarchical model. J Cell Sci 2000;113:1161-1166.
4. Smith JR, Pochampally R, Perry A et al. Isolation of a highly clonogenic and multipotential subfraction of adult stem cells from bone marrow stroma. STEM CELLS 2004;22:823-831.
5. Horwitz EM, Prockop DJ, Fitzpatrick LA et al. Transplantability and therapeutic effects of bone marrow-derived mesenchymal cells in children with osteogenesis imperfecta. Nat Med 1999;5:309-313.
6. Orlic D, Kajstura J, Chimenti S et al. Bone marrow cells regenerate infarcted myocardium. Nature 2001;410:701-705.
7. Iyer SS, Rojas M. Anti-inflammatory effects of mesenchymal stem cells: Novel concept for future therapies. Expert Opin Biol Ther 2008;8:569-581.
8. Silva GV, Litovsky S, Assad JA et al. Mesenchymal stem cells differentiate into an endothelial phenotype, enhance vascular density, and improve heart function in a canine chronic ischemia model. Circulation 2005;111:150-156.
9. Tang YL, Zhao Q, Zhang YC et al. Autologous mesenchymal stem cell transplantation induce VEGF and neovascularization in ischemic myocardium. Regul Pept 2004;117:3-10.
10. Kinnaird T, Stabile E, Burnett MS et al. Local delivery of marrow-derived stromal cells augments collateral perfusion through paracrine mechanisms. Circulation 2004;109: 1543-1549.
11. Sun Y, Li W, Lu Z et al. Rescuing replication and osteogenesis of aged mesenchymal stem cells by exposure to a young extracellular matrix. FASEB J 2011;25:1474-1485.
12. van Poll D, Parekkadan B, Borel Rinkes IHM et al. Mesenchymal stem cell therapy for protection and repair of injured vital organs. Cell Mol Bioeng 2008;1:42-50.
13. Deans RJ, Moseley AB. Mesenchymal stem cells: Biology and potential clinical uses. Exp Hematol 2000;28:875-884.
14. Le Blanc K. Immunobiology of human mesenchymal stem cells and future use in hematopoietic stem cell transplantation. Biology Blood Marrow Transplant 2005;11:321-334.
15. Ringdén O, Uzunel M, Sundberg B et al. Tissue repair using allogeneic mesenchymal stem cells for hemorrhagic cystitis, pneumomediastinum and perforated colon. Leukemia 2007;21:2271-2276.
16. U.S. National Library of Medicine, U.S. National Institutes of Health, U.S. Department of Health and Human Services. ClinicalTrials. gov, Lester Hill National Center for Biomedical Communications.
17. Javazon EH, Beggs KJ, Flake AW. Mesenchymal stem cells: Paradoxes of passaging. Exp Hematol 2004;32:414-425.
18. Ankrum J, Karp JM. Mesenchymal stem cell therapy: Two steps forward, one step back. Trends Mol Med 2010;16:203-209.
19. Dominici M, Le Blanc K, Mueller I et al. Minimal criteria for defining multipotent mesenchymal stromal cells: The International Society for Cellular Therapy position statement. Cytotherapy 2006;8:315-317.
20. Bieback K, Schallmoser K, Kluter H et al. Clinical protocols for the isolation and expansion of mesenchymal stromal cells. Transfus Med Hemother 2008;35:286-294.
21. Sotiropoulou PA, Perez SA, Papamichail M. Clinical grade expansion of human bone marrow mesenchymal stem cells. Methods Mol Biol 2007;407:245-263.
22. Chamberlain G, Fox J, Ashton B et al. Concise review: Mesenchymal stem cells: Their phenotype, differentiation capacity, immunological features, and potential for homing. STEM CELLS 2007;25:2739-2749.
23. Stroncek DF, Jin P, Wang E et al. Potency analysis of cellular therapies: The emerging role of molecular assays. J Transl Med 2007;5: 24.
24. Stanley PE. A review of bioluminescent ATP techniques in rapid microbiology. J Biolumin Chemilumin 1989;4:375-380.
25. Deskins DL, Ardestani S, Young PP. The polyvinyl alcohol sponge model implantation. J Vis Exp 2012;(62):3885.
26. Alfaro MP, Vincent A, Saraswati S et al. sFRP2 suppression of bone morphogenic protein (BMP) and Wnt signaling mediates mesenchymal stem cell (MSC) self-renewal promoting engraftment and myocardial repair. J Biol Chem 2010;285:35645-35653.
27. Alfaro MP, Pagni M, Vincent A et al. A Wnt modulator sFRP2 enhances mesenchymal stem cell engraftment, granulation tissue formation and myocardial repair. Proc Natl Acad Sci USA 2008;105:18366-18371.
28. Efron DT, Barbul A. Subcutaneous sponge models. Methods Mol Med 2003;78: 83-93.
29. Andrade SP, Ferreira MA. The sponge implantmodel of angiogenesis. Methods Mol Biol 2009;467:295-304.
30. Saraswati S, Alfaro MP, Thorne CA et al. Pyrvinium, a potent small molecule Wnt inhibitor, promotes wound repair and post-MI cardiac remodeling. PLoS One 2010;5: e15521.
31. Russell KC, Lacey MR, Gilliam JK et al. Clonal analysis of the proliferation potential of human bone marrow mesenchymal stem cells as a function of potency. Biotechnol Bioeng 2011;108:2716-2726.
32. Russell KC, Phinney DG, LaceyMRet al. In vitro high-capacity assay to quantify the clonal heterogeneity in trilineage potential of mesenchymal stem cells reveals a complex hierarchy of lineage commitment. STEM CELLS 2010;28: 788-798.
33. Lee CC, Christensen JE, Yoder MC et al. Clonal analysis and hierarchy of human bone marrow mesenchymal stem and progenitor cells. Exp Hematol 2010;38:46-54.
34. Lee RH, Hsu SC, Munoz J et al. A subset of human rapidly self-renewing marrow stromal cells preferentially engraft in mice. Blood 2006; 107:2153-2161.
35. Digirolamo CM, Stokes D, Colter D et al. Propagation and senescence of human marrow stromal cells in culture: A simple colonyforming assay identifies samples with the greatest potential to propagate and differentiate. Br J Haematol 1999;107:275-281.
36. Golebiewska A, Brons NH, Bjerkvig R et al. Critical appraisal of the side population assay in stem cell and cancer stem cell research. Cell Stem Cell 2011;8:136-147.